188 related articles for article (PubMed ID: 12960319)
1. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
Baxevanis CN; Gritzapis AD; Papamichail M
J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
Kawamura T; Seki S; Takeda K; Narita J; Ebe Y; Naito M; Hiraide H; Abo T
Cell Immunol; 1999 May; 193(2):219-25. PubMed ID: 10222065
[TBL] [Abstract][Full Text] [Related]
3. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
Hafner M; Falk W; Echtenacher B; Männel DN
Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
[TBL] [Abstract][Full Text] [Related]
6. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
7. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18.
Lauwerys BR; Garot N; Renauld JC; Houssiau FA
J Immunol; 2000 Aug; 165(4):1847-53. PubMed ID: 10925263
[TBL] [Abstract][Full Text] [Related]
8. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.
Fogler WE; Volker K; Watanabe M; Wigginton JM; Roessler P; Brunda MJ; Ortaldo JR; Wiltrout RH
J Immunol; 1998 Dec; 161(11):6014-21. PubMed ID: 9834083
[TBL] [Abstract][Full Text] [Related]
9. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells.
Leite-De-Moraes MC; Hameg A; Pacilio M; Koezuka Y; Taniguchi M; Van Kaer L; Schneider E; Dy M; Herbelin A
J Immunol; 2001 Jan; 166(2):945-51. PubMed ID: 11145671
[TBL] [Abstract][Full Text] [Related]
10. Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex.
Carnaud C; Gombert J; Donnars O; Garchon H; Herbelin A
J Immunol; 2001 Feb; 166(4):2404-11. PubMed ID: 11160299
[TBL] [Abstract][Full Text] [Related]
11. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12.
Takeda K; Hayakawa Y; Atsuta M; Hong S; Van Kaer L; Kobayashi K; Ito M; Yagita H; Okumura K
Int Immunol; 2000 Jun; 12(6):909-14. PubMed ID: 10837418
[TBL] [Abstract][Full Text] [Related]
12. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.
Smyth MJ; Taniguchi M; Street SE
J Immunol; 2000 Sep; 165(5):2665-70. PubMed ID: 10946296
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo.
Assarsson E; Kambayashi T; Sandberg JK; Hong S; Taniguchi M; Van Kaer L; Ljunggren HG; Chambers BJ
J Immunol; 2000 Oct; 165(7):3673-9. PubMed ID: 11034371
[TBL] [Abstract][Full Text] [Related]
14. Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells.
Dobashi H; Seki S; Habu Y; Ohkawa T; Takeshita S; Hiraide H; Sekine I
Hepatology; 1999 Aug; 30(2):430-6. PubMed ID: 10421651
[TBL] [Abstract][Full Text] [Related]
15. Interferon gamma production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking.
Arase H; Arase N; Saito T
J Exp Med; 1996 May; 183(5):2391-6. PubMed ID: 8642351
[TBL] [Abstract][Full Text] [Related]
16. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
17. IL-4-producing NK T cells are biased towards IFN-gamma production by IL-12. Influence of the microenvironment on the functional capacities of NK T cells.
Leite-De-Moraes MC; Moreau G; Arnould A; Machavoine F; Garcia C; Papiernik M; Dy M
Eur J Immunol; 1998 May; 28(5):1507-15. PubMed ID: 9603455
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells.
Eberl G; Lees R; Smiley ST; Taniguchi M; Grusby MJ; MacDonald HR
J Immunol; 1999 Jun; 162(11):6410-9. PubMed ID: 10352254
[TBL] [Abstract][Full Text] [Related]
19. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
[TBL] [Abstract][Full Text] [Related]
20. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
